echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Prostate: In transitional zone prostate cancer, which 18 F-DCFPyL PET diagnosis or MRI diagnosis is better?

    Prostate: In transitional zone prostate cancer, which 18 F-DCFPyL PET diagnosis or MRI diagnosis is better?

    • Last Update: 2021-10-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Prostate cancer (PCa) is one of the most common malignant urinary system tumors in men


    PCa mainly occurs in the peripheral area of ​​the prostate, only about 30% occurs in the TZ PCa mainly occurs in the peripheral area of ​​the prostate, and only about 30% occurs in the TZ

    Recently, researchers from China published an article in the "Prostate" magazine, aiming to compare 18F-DCFPyL positron emission tomography (PET) and multi-parameter magnetic resonance imaging (mp-MRI) in diagnosing transitional zone (TZ) prostate cancer (PCa) performance


    To compare the performance of 18F-DCFPyL positron emission tomography (PET) and multi-parameter magnetic resonance imaging (mp-MRI) in the diagnosis of transition zone (TZ) prostate cancer (PCa).


    The study was designed retrospectively and included 20 patients receiving 18 F-DCFPyL PET/MRI and 32 patients receiving 18 F-DCFPyL PET/CT and MRI from January 2019 to June 2020


    It was found that out of 52 patients, 43 had TZ PCa


    18 Diagnostic performance of F-DCFPyL PET and MRI in TZ PCa

    18 Diagnostic performance of F-DCFPyL PET and MRI in TZ PCa

    In summary, these results show that the interpretation results of 18 F-DCFPyL PET have almost nothing to do with the doctor’s experience.


    The interpretation result of 18 F-DCFPyL PET has almost nothing to do with the doctor’s experience.


    Original source:

    Yachao Liu, Yanliang Dong, Jiajin Liu et al.


    Comparison between 18 F-DCFPyL PET and MRI for the detection of transition zone prostate cancer

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.